Neoadjuvant durvalumab and tremelimumab in combination with chemotherapy in newly diagnosed advanced high-grade serous ovarian cancer (iPRIME): a randomized, non-comparative phase 2 trial using chemotherapy response score as the primary endpoint
Cancer Immunology, Immunotherapy · 31.10.2026
DOI: 10.1007/s00262-026-04589-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 31.10.2026. Verfasst von Tarek Meniawy und 14 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Astra.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Förderung
- Astra
Zitieren
APA
Meniawy, T., Lombard, J., Shannon, C., Mileshkin, L., Goh, J., Gao, B., Webber, K., Palayoor, N. D., Stewart, C., Fahey, M. T., Opar, P., Andrews, J., Weatherall, K., Boo, M., & Friedlander, M. (2026). Neoadjuvant durvalumab and tremelimumab in combination with chemotherapy in newly diagnosed advanced high-grade serous ovarian cancer (iPRIME): a randomized, non-comparative phase 2 trial using chemotherapy response score as the primary endpoint. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04589-4
Vancouver
Meniawy T, Lombard J, Shannon C, Mileshkin L, Goh J, Gao B, et al. Neoadjuvant durvalumab and tremelimumab in combination with chemotherapy in newly diagnosed advanced high-grade serous ovarian cancer (iPRIME): a randomized, non-comparative phase 2 trial using chemotherapy response score as the primary endpoint. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-026-04589-4
BibTeX
@article{Meniawy2026,
author = {Meniawy, Tarek and Lombard, Janine and Shannon, Catherine and Mileshkin, Linda and Goh, Jeffrey and Gao, Bo and Webber, Kate and Palayoor, Navin David and Stewart, Colin and Fahey, Michael T. and Opar, Petra and Andrews, John and Weatherall, Kate and Boo, Marilyn and Friedlander, Michael},
title = {Neoadjuvant durvalumab and tremelimumab in combination with chemotherapy in newly diagnosed advanced high-grade serous ovarian cancer (iPRIME): a randomized, non-comparative phase 2 trial using chemotherapy response score as the primary endpoint},
journal = {Cancer Immunology, Immunotherapy},
year = {2026},
doi = {10.1007/s00262-026-04589-4}
}
EUVIMED